Efficiency of antiviral treatment in COVID-19
| Autor: | Camelia Cristina Diaconu, Florin Banica, Simona Bungau, Delia Mirela Tit, Ioana Hodisan, Nicoleta Negrut, Tapan Behl, Ruxandra C. Marin, Delia Carmen Nistor-Cseppento, Adriana Codrean |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lopinavir General Medicine Articles Gastroenterology Immunology and Microbiology (miscellaneous) Internal medicine medicine Ritonavir Respiratory system business Adverse effect Darunavir medicine.drug Oxygen saturation (medicine) |
| Zdroj: | Exp Ther Med |
| Popis: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is responsible for generating a global effort to discover urgent therapeutic solutions to limit the human damage caused by COVID-19. In the period of April to June 2020, 105 patients diagnosed with COVID-19 met the conditions for inclusion in the present study. They were treated with antiviral therapy according to local guidelines: D group (53 cases), treated with darunavir/ritonavir (DRV/r); and K group (52 cases), treated with lopinavir/ritonavir (LPV/r). Patients from the K group required 7.5 days of hospitalization less compared to those from the D group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|